Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Citi ups rating on Croda following Iberchem deal

Fri 20 November 2020 08:53 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Citi has upgraded Croda International to a 'buy' following the chemicals group's €820m acquisition of Spain's Iberchem.

The UK firm, which has secured a contract to supply ingredients for Pfizer's Covid-19 vaccine, announced on Wednesday that it had agreed to buy the fragrances firm, a specialist in emerging markets, from its private equity owners.

Citi said the deal was a "step change".

Analyst Mubasher Chaudhry said: "The deal, we think, provides Croda with access to the fastest-growing regions within the fragrance space, the ability to realise significant revenue synergies through cross-selling, and an opportunity to partake in what is a rapidly consolidating industry.

"Double digit growth in life sciences, increased markets to growing in personal care, and a strong balance sheet to support inorganic growth presents a compelling investment case."

Around 83% of Iberchem sales are in emerging markets.

As at 0935 GMT, shares in Croda were ahead nearly 2% at 6,358.0p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More stockbroker tips from ShareCast

    Latest economy and stock market articles